- Home
- SKIN vs VXRT Comparison
SKIN vs VXRT Comparison
Compare SKIN & VXRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKIN
- VXRT
- Stock Information
- Founded
- SKIN 1997
- VXRT N/A
- Country
- SKIN United States
- VXRT United States
- Employees
- SKIN N/A
- VXRT N/A
- Industry
- SKIN Package Goods/Cosmetics
- VXRT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SKIN Consumer Discretionary
- VXRT Health Care
- Exchange
- SKIN Nasdaq
- VXRT Nasdaq
- Market Cap
- SKIN 207.3M
- VXRT 170.2M
- IPO Year
- SKIN N/A
- VXRT N/A
- Fundamental
- Price
- SKIN $1.61
- VXRT $0.71
- Analyst Decision
- SKIN Hold
- VXRT Buy
- Analyst Count
- SKIN 5
- VXRT 1
- Target Price
- SKIN $2.55
- VXRT $4.00
- AVG Volume (30 Days)
- SKIN 403.4K
- VXRT 1.2M
- Earning Date
- SKIN 03-07-2025
- VXRT 03-13-2025
- Dividend Yield
- SKIN N/A
- VXRT N/A
- EPS Growth
- SKIN N/A
- VXRT N/A
- EPS
- SKIN N/A
- VXRT N/A
- Revenue
- SKIN $347,620,000.00
- VXRT $16,760,000.00
- Revenue This Year
- SKIN N/A
- VXRT $128.77
- Revenue Next Year
- SKIN $1.79
- VXRT N/A
- P/E Ratio
- SKIN N/A
- VXRT N/A
- Revenue Growth
- SKIN N/A
- VXRT 303.27
- 52 Week Low
- SKIN $0.91
- VXRT $0.52
- 52 Week High
- SKIN $5.17
- VXRT $1.43
- Technical
- Relative Strength Index (RSI)
- SKIN 47.61
- VXRT 48.01
- Support Level
- SKIN $1.51
- VXRT $0.68
- Resistance Level
- SKIN $1.74
- VXRT $0.78
- Average True Range (ATR)
- SKIN 0.09
- VXRT 0.05
- MACD
- SKIN -0.00
- VXRT -0.00
- Stochastic Oscillator
- SKIN 43.48
- VXRT 48.85
About SKIN The Beauty Health Company
The Beauty Health Co is a category-creating beauty health company that along with its subsidiaries designs, develops, manufactures, markets, and sells esthetic technologies and products. The company's brand portfolio includes Hydrafacial, SkinStylus, and Keravive, offering Syndeo device, SkinStylus SteriLock Microsystem, Keravive Peptide Solution and other products.
About VXRT Vaxart Inc
Vaxart Inc is a clinical-stage biotechnology company. It focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases. The products under its tablet pipeline consist of the treatment of Coronavirus, Norovirus, Seasonal Influenza, RSV(respiratory syncytial virus), and HPV(Human papillomavirus) Therapeutic. It operates in a single segment, which is the discovery and development of oral recombinant protein vaccines. Geographically all the business activity functions through the region of the United States.